Account
Insider Insights
01.02.2022
NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
Articles
17.01.2022
COVID-19 Two Year Review

As we enter 2022, we are approaching the two-year anniversary of the COVID-19 pandemic spreading acr...

Read more
Articles
10.01.2022
Conducting a HTA review

Reviewing previous HTA submissions can provide valuable insights that can help manufacturers prepare...

Read more
Publications
03.12.2021
Highly specialised technologies process

Is the National Institute for Health and Care Excellence (NICE) becoming more efficient in evaluatin...

Read more
Publications
03.12.2021
Orphan drug status benefit

The purpose of this study is to compare the assessments of orphan and non-orphan drugs by NICE.

Read more
Articles
22.11.2021
NICE cost effective medicines

When making a decision about the approval of a new product NICE (National Institute for Health and C...

Read more
Articles
17.11.2021
Head of agencies HAG

The Head of Agency Group (HAG) is a recently launched network created by the European Health Technol...

Read more
Articles
30.06.2021
Clinical trial design for HTA

Clinical evidence relating to therapeutic efficacy and safety is one of the most valuable criteria o...

Read more
Articles
25.06.2021
EU Joint HTA Process Finally Agreed

The European Parliament and Council negotiators reached a provisional agreement on a joint health te...

Read more
Articles
02.06.2021
EU Joint HTA EESC publish its positive option

Are we one step closer to an EU Health Technology Assessment body. The EESC publish its positive opi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.